1. Scrip
  2. >>Business

Why Kevin Lee Left Pfizer To Push Bicycles

 
• By Sukaina Virji

The pharma wires have been busy recently with news of droves of big pharma executives leaving their posts to take up the top spot at small biotech companies. The latest is Dr Kevin Lee, the former chief scientific officer of the Rare Disease Research Unit at Pfizer. Here he tells Scrip's Sukaina Virji what prompted him to leave the glamorous life of a big pharma executive and take up his new job as chief executive officer of tiny Cambridge, UK-based biotech Bicycle Therapeutics.

The pharma wires have been busy recently with news of droves of big pharma executives leaving their posts to take up the top spot at small biotech companies. The latest is Dr Kevin Lee, the former chief scientific officer of the Rare Disease Research Unit at Pfizer. Here he tells Scrip's Sukaina Virji what prompted him to leave the glamorous life of a big pharma executive and take up his new job as chief executive officer of tiny Cambridge, UK-based biotech Bicycle Therapeutics.

Scrip: Pfizer to Bicycle Therapeutics is a major career move. Why did you make it?

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

More from Scrip

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial